Manganese chloride Clinical Trials

Size	Price	Qty
25mg	USD 147

Clinical Trials

Multiple clinical trials evaluate manganese chloride across several oncological indications, including solid tumors, lymphoma, biliary tract cancer, ovarian cancer, and pancreatic cancer. Primarily Phase 1 and Phase 2 investigations sponsored by the Chinese PLA General Hospital, these studies assess safety, tolerability, and preliminary therapeutic efficacy in monotherapy and combination regimens. With recruitment statuses ranging from completed to unknown, these trials reflect the ongoing early-to-mid-stage development of manganese-based immunotherapy protocols.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04873440	UNKNOWN	Solid Tumor; Lymphoma	Chinese PLA General Hospital	2021-05-06	PHASE1; PHASE2
NCT03989336	COMPLETED	Ovarian Cancer	Chinese PLA General Hospital	2020-12-23	PHASE2
NCT03989310	UNKNOWN	Pancreatic Cancer	Chinese PLA General Hospital	2019-03-01	PHASE1; PHASE2
NCT04004234	UNKNOWN	Biliary Tract Cancer (BTC)	Chinese PLA General Hospital	2019-03-01	PHASE1; PHASE2
NCT03991559	UNKNOWN	Solid Tumor; Lymphoma	Chinese PLA General Hospital	2018-11-01	PHASE1

(data from https://clinicaltrials.gov, updated on 2021-05-05)

Check the Manganese chloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Manganese chloride dissociates to release manganese ions that bind key cytosolic signaling proteins, such as cyclic GMP-AMP synthase and STING, thereby enhancing downstream type I interferon pathway induction. This innate immune activation stimulates immune cell priming and enhances anti-tumor immunity, providing therapeutic rationale for its clinical investigation in solid tumors, lymphoma, and pancreatic cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).